Insights

Why Pfizer Stock Rose Today While the Market Tanked

What happened
Over the past few years, popular pharmaceutical company Pfizer (NYSE: PFE) has proven to be a resilient stock during market downturns. That happened on Tuesday when the shares eked out a slight gain as the S&P 500 suffered a nearly 3% decline. Investors were cheered by some good news emanating from the laboratory.
So what
Pfizer and its partner, vaccine-focused biotech Valneva (NASDAQ: VALN), unveiled data from the phase 2 pediatric clinical trial of VLA15, their Lyme disease vaccine candidate. The data indicates that the recipients, who were ages 5 to 17, experienced a more immunogenic response than adults receiving the jab. The vaccine was safe and well-tolerated by the recipients; no related serious adverse events were observed.

Image source: Getty Images.

That’s a very positive sign; in a preceding phase 2 study conducted on 246 adults, VLA15 met its primary endpoint of demonstrating that it was immunogenic and produced high antibody responses one month after the administration of the vaccination cycle.
Pfizer and Valneva now plan to include pediatric recipients in the phase 3 trial they are devising for VLA15. The two companies also intend to submit the phase 2 pediatric trial’s data for publication and presentation. Pfizer quoted its head of vaccine research and development Kathrin Jansen as saying:

These positive pediatric data mark an important step forward in the ongoing development of VLA15, and we are excited to continue working with Valneva to potentially help protect both adults and children from Lyme disease.

Now what
The continued, solid performance of VLA15 is heartening, particularly considering that Lyme disease, a bacterial illness spread by ticks, is the most common vector-borne affliction in this country. According to recent estimates cited by the Centers for Disease Control and Prevention (CDC), roughly 476,000 could get Lyme disease annually in the U.S.
Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. –

What happened

Over the past few years, popular pharmaceutical company Pfizer (NYSE: PFE) has proven to be a resilient stock during market downturns. That happened on Tuesday when the shares eked out a slight gain as the S&P 500 suffered a nearly 3% decline. Investors were cheered by some good news emanating from the laboratory.

So what

Pfizer and its partner, vaccine-focused biotech Valneva (NASDAQ: VALN), unveiled data from the phase 2 pediatric clinical trial of VLA15, their Lyme disease vaccine candidate. The data indicates that the recipients, who were ages 5 to 17, experienced a more immunogenic response than adults receiving the jab. The vaccine was safe and well-tolerated by the recipients; no related serious adverse events were observed.

Image source: Getty Images.

That’s a very positive sign; in a preceding phase 2 study conducted on 246 adults, VLA15 met its primary endpoint of demonstrating that it was immunogenic and produced high antibody responses one month after the administration of the vaccination cycle.

Pfizer and Valneva now plan to include pediatric recipients in the phase 3 trial they are devising for VLA15. The two companies also intend to submit the phase 2 pediatric trial’s data for publication and presentation. Pfizer quoted its head of vaccine research and development Kathrin Jansen as saying:

These positive pediatric data mark an important step forward in the ongoing development of VLA15, and we are excited to continue working with Valneva to potentially help protect both adults and children from Lyme disease.

Now what

The continued, solid performance of VLA15 is heartening, particularly considering that Lyme disease, a bacterial illness spread by ticks, is the most common vector-borne affliction in this country. According to recent estimates cited by the Centers for Disease Control and Prevention (CDC), roughly 476,000 could get Lyme disease annually in the U.S.

Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Trade The World Anywhere & Anytime!

Mobile app platform with over 50,000 global listed securities across 12 markets (over 70% global market capitalisation), right from your Android or iOS device.

Integrated with exclusive trading idea and investment analysis tools to help you find actionable insight on virtually every financial instrument across our 12 global markets, to help you optimise your trading strategies.

Refer Your Friends

Tell your friends about Monex and gift them FREE access to our trading tools.

  • This field is for validation purposes and should be left unchanged.

We respect your privacy and will only send this one email notification to your friends. 

Share With Your Friends

Share on facebook
Share on twitter
Share on linkedin

Monex Trading Tools Access and Usage Terms

The Monex Trading Tools (referred to as ‘tools’ hereafter) are available to you inside your client portal;


To activate access to the tools, you must have a verified and approved trading account and have made a deposit of at least AUD $1000.


An active and funded account with a positive trading balance is required to continue to have access to the tools;


Although the tools are available to you indefinitely, Monex Securities may at it’s discretion disable access to the tools in the future;


Monex securities reserves the right to change these terms and conditions from time to time, as it sees fit, without notice.

Important Notice
iOS & Android - 12 International Markets & Over 70% Global Market Cap. $0 Brokerage On US & HK* Trades. Click Here!